Page 31 - Pharma

Aurobindo Pharma receives US FDA nod for rivastigmine capsules

The approved product, rivastigmine tartrate capsules, is generic version of Novartis' Exelon and has an estimated market size of $ 26.7 million

Biocon receives regulatory approval for insulin glargine in Japan

With this approval, Biocon aims to capture a significant share of the Japanese glargine market of $ 144 million, which is the second largest market outside of North America & Europe

Smith & Nephew to launch Blue Belt's Navio surgical system in India

Smith & Nephew intends to expand the Navio platform into total knee, bi-cruciate retaining knee and revision knee implants

Sun Pharma buys Novartis' 14 brands for $ 293 mn in Japan

With the acquisition of these brands, which have combined annualised revenues of approximately $ 160 million, Sun Pharma enters Japanese prescription market

Sun Pharma partners AstraZeneca to sell diabetes drug dapagliflozin in India

Under the agreement, both companies will promote, market & distribute dapagliflozin in India under different brand names, while AstraZeneca will retain the IPRs to dapagliflozin

Dechra acquires US-based pet pharma firm Putney for $ 200 mn

The acquisition of Putney will significantly strengthen the UK-based Dechra's position in the US and will provide high quality FDA approved veterinary products and strengthen its pipeline

Cipla hikes stake in US-based Chase Pharmaceuticals to 16.7%

Mumbai-based pharma major has invested additional $ 3 million to raise the stake in Chase, in which Cipla had invested $1.5 million in May 2014 to acquire 14.6% stake

Orchid Pharma gets shared 180-day exclusivity rights for Parkinson's drug in US

This was possible after the company received final approval for the drug, rasagiline mesylate tablets (0.5 mg and 1 mg), from US drug regulator

Glenmark receives tentative approval from US FDA for locosamide oral solution

Locosamide oral solution, used for treating epilepsy, is the generic version of UCB Inc's Vimpat, the patent of which is scheduled to expire on March 17, 2022

US FDA gives EIR to Torrent Pharma's Dahej plant

Dahej plant, which earlier received approval from EU Germany, was set up by Torrent to cater mainly to the regulated international markets like US, Brazil, Germany etc

Biocon ties up with Mexico's PiSA to tap insulin market in US

Through this collaboration, Biocon will introduce its rh-insulin product to address the $ 2 billion market opportunity in the US

Sanofi Pasteur and MSD end vaccines JV in Europe

The 50:50 joint venture Sanofi Pasteur MSD was created in 1994 to develop and commercialise vaccines originating from both companies' pipelines

European drug regulator suspends CEP certificate for Anuh Pharma's 3 products

EDQM has suspended the Certificate of Suitability (CEP) for Anuh Pharma's three APIs - erythromycin ethyl succinate, erythromycin and pyrazinamide

Drugs short supply in US offers huge opportunity for Indian pharma industry

Out of the 62 drugs that are in short supply in the US, Indian pharma industry exports only about 20 drugs. This indicates that there exists a huge potential for Indian drug manufacturers

Global Vectra and US-based Era to offer helicopter emergency medical services

Two companies will collaborate on an exclusive basis to provide medical assistance to casualties following accidents and disasters, evacuate critical care patients, etc within India

Doctors Without Borders challenges Pfizer's pneumonia vaccine patent in India

With this, MSF or Doctors Without Borders, which claims Pfizer vaccine is highly priced, has become the first medical organisation to challenge a vaccine (biosimilar) patent in India

FSSAI launches project 'Clean Street Food'

In the first phase, the project aims to raise the safety standards of foods sold on streets across New Delhi by training 20,000 roadside vendors on aspects of health and hygiene

Apollo Hospitals completes acquisition of 51% stake in Assam Hospitals

Apollo Hospitals completes acquisition of 51% stake in Assam Hospitals

Dottikon Exclusive Synthesis to invest $101 million in APIs facility

The investment will consist of the creation of additional chemical process development and production capacities for active pharmaceutical ingredients (APIs)

Pfizer stops production of Corex cough syrup

The move follows a government notification banning over 344 drug combinations, which included fixed dose combination of chlopheniramine maleate and codeine syrup